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Background
Persistent allergic rhinitis has significant effects on the quality of life (QOL), especially on sleep
and work performance, and is associated with specific psychiatric syndromes.
Aim
The aim of the present study was to verify the efficacy of combined desipramine and
levocetirizine in the treatment of psychological stress related to persistent allergic rhinitis, and
to thereby improve the QOL of the patient.
Patients and methods
A total of 132 psychologically stressed persistent allergic rhinitis patients (positive Kessler
Psychological Distress Scale scores ≥12) were randomly divided into two groups: the control
group, which received levocetirizine, and the study group, which received levocetirizine
plus desipramine. QOL for all patients was assessed by using a seven-point scale after the
treatment period.
Results
There was a highly statistically significant better QOL in the study group (6.79) compared with
the control group (2.21) (t-test=15.17 and P = 0.0001).
Conclusion
Desipramine and levocetirizine have a better effect on the QOL outcomes in the treatment of
patients with persistent allergic rhinitis, and having psychological stress disorders.
Level of evidence: 3b.
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Introduction
Persistent allergic rhinitis has a significant effect on
quality of life (QOL), especially on sleep and work
performance [1].
Allergic rhinitis classification actually reflects
the clinical course with its burden on QOL
into: intermittent (total duration <4 weeks) or
persistent (symptoms continue throughout the
whole year); according to severity, it is classified as
follows: either mild (patients are generally able to
sleep normally and perform normal activities) or
moderate/severe (significantly affects sleep and daily
activities) [2].
A strong relationship between persistent allergic
rhinitis and specific psychiatric syndromes has been
illustrated in many studies [3].
In their studies, Katotomichelakis et al. [4] mentioned
a 1.7 times higher psychological stress symptoms in
persistent allergic rhinitis patients; in addition, Garg
and Silverberg [5] found a higher rate of panic disorder
with major depression symptoms among the same
population.

Many theories demonstrate these relationship as either
immune-related illnesses [6] through the presence
of cytokines [7]; sleep disruption with subsequently
negative effects on psychiatric symptoms [8]; or genetic
risk between both allergies and depression [9].
Levocetirizine (5 mg/day) is a potent H1-receptor
antagonist with proven efficacy as a therapeutic option
in persistent allergic rhinitis improving the nasal
symptoms, and thereby improves significantly the
impaired QOL [10].
Desipramine is a tricyclic antidepressant, beside its
indication for the treatment of depression and improve
patients mood; it has antihistaminic properties,
affecting histamine H1 receptors by regulating Treg
and Th17 cells [11,12].
The present study aimed to verify the efficacy of
combined dose of desipramine and levocetirizine in
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the treatment of psychological stress-persistent allergic
rhinitis and thereby improve QOL outcomes.
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indicate positive psychological distress (who were
included in the study) [14].
Randomization

Patients and methods
Design, setting and participants

A double-blinded, randomized clinical trial was
conducted in the Otolaryngology Department, Suez
Canal University Hospital (Ismailia, Egypt), from
December 2008 to June 2011. The study protocol was
approved by the local ethics committee, and written
informed consent was obtained from all patients.

Patients were randomly divided into the study and the
control group using a blocked randomization scheme
by using computer-generated random numbers.
The control group received levocetirizine (5 mg/day) [10]
for 30 days and the study group received levocetirizine
(5 mg/day) plus desipramine (25 mg/day) for the same
period of time [12].
Outcome measurement assessment

Inclusion and exclusion criteria

A total of 132 psychologically stressed persistent
allergic rhinitis patients (longer than 4 days/week
and for >4 consecutive weeks) [13] and positive to
Kessler Psychological Distress Scale scores of greater
than or equal to 12 were included in our study. Kessler
Psychological Distress Scale scores demonstrate the
responses to the K5 questions with a minimum possible
score of 5 and a maximum possible score of 25. Low
scores, 5–11, indicate negative psychological distress
and high scores, 12–25, indicate positive psychological
distress [14].
In contrast, patients negative to Kessler Psychological
Distress Scale scores (5–11), with rhinitis
medicamentosa, receiving drugs known to induce
nasal obstruction (e.g. β-blockers), and with previous
nasal surgery, hormonal therapy, pregnancy, lactation,
occupational dust exposure, nasal polyposis, or
rhinosinusitis, were excluded from the study population.

The primary outcome was the effect of treatment on
QOL after 30 days from treatment initiation using
a seven-point scale for assessing severity of allergic
rhinitis on sleep pattern at night, work performance,
and social and/or recreational activities [15].
Statistical analysis

Data collected were processed using SPSS (version 23;
SPSS Inc., Chicago, Illinois, USA). Quantitative data
were expressed as means±SD, whereas qualitative
data were expressed as numbers and percentages.
Student’s t-test was used to compare the significance
of difference for quantitative variables that followed a
normal distribution.
Ethical considerations

Written informed consent was obtained from all
patients. The local ethics committee approved the
study.

Study plane

All patients were subjected to complete history taking
including allergic rhinitis symptoms assessment
using the visual analogue scale (VAS), which assesses
subjective symptoms, with 0 indicating no symptoms
and10 indicating severe and/or constant symptoms.
A complete ENT examination, with rigid nasal
endoscopic examinations (Hopkins II Endoscope;
Karl Storz, Tuttlingen, Germany), paranasal sinus
computed tomography scan, and skin prick test, was
carried out.
Psychological evaluation of Kessler Psychological
Distress Scale scores demonstrates the responses to
the 25 questions, with a minimum possible score of
5 and a maximum possible score of 25. Low scores,
5–11, indicate negative psychological distress (who
were excluded from the study) and high scores, 12–25,

Results
Out of a total of 132 psychological stressed persistent
allergic rhinitis patients, with a mean age of
41.2 ± 6.8 years [81 (61.4%) women and 51 (38.6%)
men], included in the study, 113 (85.6%) patients
showed the main symptoms of sneezing, followed by
itchy nose in 95 (71.9%) patients, nasal obstruction
in 82 (62.1%), patients and watery rhinorrhea in
79 (59.8%) patients, whereas the main finding during
nasal examination was pale, congested, bluish mucosa
in 115 (87.1%) patients.
Patients were divided randomly into two equal groups:
the control group (n = 66) received levocetirizine
(5 mg/day) for 30 days; and the study group (n = 66)
received levocetirizine (5 mg/day) plus desipramine
(25 mg/day) for the same period of time.
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The mean intensity of nasal symptoms according to
VAS before treatment in the control group was sneezing
9.35, whereas it was 9.09 in the study group: nasal
obstruction was 9.13 and 8.98, respectively; watery
rhinorrhea was 7.97 and 8.06, respectively; and, finally,
itchy nose was 7.43 and 7.81, respectively, without any
statistically significance difference between the two
groups (Table 1).

as according to the QOL scale, 1–2 means poor QOL,
3–4 fair QOL, 5–6 average QOL, and seven means
good QOL. Overall, 87.9% patients in the study group
reported a good QOL scale score compared with only
4.5% in the control group, with a high statistically
significant difference (Table 3 and Fig. 1).

After 30 days, the mean intensity of nasal symptoms
according to VAS in the control group was sneezing
3.91, whereas it was 1.08 in the study group, nasal
obstruction was 4.26 and 1.21, respectively; watery
rhinorrhea was 4.92 and 1.01, respectively, and itchy
nose was 3.24 and 1.57, respectively. There was
highly statistically significant improvement in the
allergic nasal symptoms of the study group (receiving
levocetirizine plus desipramine) compared with the
control group (only levocetirizine) (Table 2).

Discussion
Persistent allergic rhinitis is a common disease with
significant burden on the QOL. Many treatment
options directed at symptomatic relief are available, but
sometimes the traditional treatment is not effective to
address all aspects of the disease burden [16].

QOL scale was calculated, and the assessment at the end
of the treatment revealed a highly significantly better
life quality for the study group (6.79) compared with
the control group (2.21) (t-test=15.17 and P = 0.0001),
Table 1 Mean degree of different allergic nasal symptoms
before treatment in both groups, for those who were positive
on the Kessler Psychological Distress Scale scores
Control
group (n=66)

Study group
(n=66)

t‑test

P value

Mean

SD

Mean

SD

Sneezing
Nasal obstruction
Watery rhinorrhea

9.35
9.13
7.97

1.14
1.97
1.72

9.09
8.98
8.06

1.82
1.81
1.47

0.46
1.05
0.93

0.927
0.672
0.591

Itchy nose

7.43

1.86

7.81

1.61

0.71

0.583

Insignificant P>0.05
Table 2 Mean degree of different allergic nasal symptoms
after treatment in both groups, for those who were positive
on the Kessler Psychological Distress Scale scores
t‑test

P value

0.82
1.14
1.09

4.04
4.26
6.85

0.0001**
0.0001**
0.0001**

1.01

7.12

0.0001**

Control
group (n=66)

Study group
(n=66)

Mean

SD

Mean

SD

Sneezing
Nasal obstruction
Watery rhinorrhea

3.91
4.26
4.92

1.14
1.34
1.09

1.08
1.21
1.01

Itchy nose

3.24

1.71

1.57

Allergic rhinitis is the sixth most prevalent chronic
condition in the world, with a high risk for developing
chronic rhinosinusitis, otitis media with effusion, nasal
polyposis, and bronchial hyperactivity, which usually
had a great burden on QOL [17].
Many authors have investigated the mechanism of
psychological stress producing persistent allergic rhinitis,
suggesting that neuropeptides and hormones released
result in immune-mediated and neurogenic inflammatory
processes, with deregulation of normal haemostatic
neural, endocrine systems leading to an increase in the
expression of the disease symptoms [18–21].
In their study, Tomljenovic et al. [22] mentioned
a strong relationship between changes in allergy
symptom scores and changes in depression scores
leading to a larger negative recurrent mood disorders
in patients with atopy and allergic rhinitis.
Lind et al. [23] mentioned in their study that there is
an associated relationship between the psychological
Figure 1

**Highly significant, P<0.01
Table 3 Quality of life scale assessment after treatment in
both groups, for those who were positive on the Kessler
Psychological Distress Scale scores
Control group
(n=66) (n (%))

Study group
(n=66) (n (%))

t‑test

P value

24 (36.4)
32 (48.5)
7 (10.6)

0 (0)
0 (0)
8 (12.1)

χ2=3.27

0.0001**

3 (4.5)

58 (87.9)

Poor
Fair
Average
Good
**Significant

Quality of life scale assessment after treatment in both groups, for
participants who were positive on the Kessler Psychological Distress
Scale scores.
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and immunological state in patients with atopy as they
are more depressive, and complain of anxiety, with
psychosomatic symptoms.
The control group received levocetirizine for 30 days
while the study group received levocetirizine plus
desipramine for the same period of time. There was
marked highly statistically significantly allergic nasal
symptoms improvement in the study group.
Allergic rhinitis associated with depression is
recognized with recommendation to treat the
depression, but fortunately, desipramine has double
action; beside being a tricyclic antidepressant agent, it
is also attenuating to the allergic nasal symptoms by
antiallergic action, as found by Zhang et al. [12] in a
study on allergic rhinitis mice.
Rao et al. [11] recognized suppression of cutaneous
histamine-induced wheal-and-flare with desipramine.
In addition, there was a highly significantly better life
quality in the study group (6.79) compared with the
control group (2.21) (t-test=15.17 and P = 0.0001) at
the end of the treatment period.
Patients with persistent allergic rhinitis usually from
poor QOL scores. Such poor QOL probably results
from a number of symptoms like difficulty getting to
sleep, waking up during the night, fatigue, mood changes
irritability, memory deficits, and lack of a good night’s
sleep as a result of their persistent nasal symptoms.That
result in forming a burden their daily life, which limits
them from doing well in their work [24].
Good QOL was reported in 87.9% patients in the
study group, whereas in the control group it was only
in 4.5%. Meanwhile, poor QOL was not reported in
the study group; it was reported by 36.4% participants
in the control group.
It should be noted that the concept of QOL differs
between individuals depending on the degree of
expectations and perceptions of the disease. Accordingly,
it varies principally depending on the standards of the
individual regards ‘personal well-being’, perception
of the surrounding world, and expectations regarding
treatment [25].
The QOL of allergic rhinitis patients was often impaired,
not only due to the typical symptoms of the disease
(sneezing, pruritus, nasal obstruction, and rhinorrhea)
but also due to the activity of the mediators such as
histamine, leukotrienes (C4 and D4), interleukins (ILs)
(IL-1β, IL-4, IL-5 and IL-13), prostaglandin D2,
substance P, and bradykinin, which participate in its
pathophysiology and can disrupt sleep [26].
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Unfortunately, a great burden associated with persistent
allergic rhinitis goes beyond the impairment of social
and physical functioning; this component is rarely
recognized or valued when the treatment is usually
prescribed with a possible causal factor of comorbidities
such as asthma and sinusitis [27].
We did not aim to point to a specific new treatment
regimen for persistent allergic rhinitis, but our raw
data showed better results for the study group, which
received desipramine plus levocetirizine, compared with
the control group, which received levocetirizine alone.
Finally, we want to point to the fact that persistent
allergic rhinitis patients do not respond to traditional
antiallergic treatment; psychosocial stresses could
be a strong etiological factor. If properly treated, the
patients’ QOL could be improved.

Conclusion
A combination of desipramine plus levocetirizine has
a better QOL outcomes in the treatment of patients
with persistent allergic rhinitis having psychosocial
stresses disorders.
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